Spectrum Pharmaceuticals Highlights Seven Abstracts Of Clinical Data At The 2012 American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago, Illinois, June 1-5, 2012

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced key presentations of clinical data, including five ZEVALIN-related poster presentations, as well as a poster presentation and one e-abstract publication of clinical data for belinostat, at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, from June 1-5, 2012.

For more information about the ASCO annual meeting and for a complete list of abstracts, please refer to the conference Web site at http://abstract.asco.org/.

The following are key ZEVALIN-related abstracts being presented at the ASCO conference:

Monday June 4, 2012, 1:15 PM - 5:15 PM Central Time
Abstract#		Type		Title		First Author		Location
8056		Poster		Effect of short-duration chemoimmunotherapy plus radioimmunotherapy on response rates in relapsed follicular lymphoma: A U.K. NCRI Lymphoma Group Study, CR UK/07/038		Illidge		S HallA2
6547		Poster		Effect of radioimmunotherapy-based conditioning for autologous stem cell transplantation on poor-risk molecular profiling in diffuse large B-cell lymphoma		Siddiqi		S HallA2
6545		Poster		A phase II trial 90y-ibritumomab tiuxetan in combination with reduced intensity regimen of fludarabine (flu) and melphalan (mel) followed by allo-HCT in patients with refractory B-cell lymphoma		Nademanee		S HallA2
6633		Poster		Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y90 (IT-Y90) in non-pretreated patients age 65 to 80 with CD20+ diffuse large B-cell lymphoma (DLBCL)		Peyrade		S HallA2
6543		Poster		Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma		Hasenkamp		S HallA2

The following are key belinostat-related abstracts:

Saturday June 2, 2012, 1:15 PM to 5:15 PM Central Time
Abstract#		Type		Title		First Author		Location
7103		Poster		A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies.		Thomas		S HallA2
Publication Abstract
Abstract#		Type		Title		First Author		Location
e18536		Publication		A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520		Persky		NA

About Non-Hodgkin’s Lymphoma

According to the National Cancer Institute ( www.cancer.gov), there are expected to be 70,130 new cases of non-Hodgkin's lymphoma diagnosed and approximately 18,940 deaths in the United States in 2012. Non-Hodgkin's lymphoma is defined as any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin's lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. These types can be divided into aggressive (fast-growing) and indolent or low grade (slow-growing) types, and they can be formed from either B-cells or T-cells. Prognosis and treatment depend on the stage and type of disease.

About ZEVALIN ^® and the ZEVALIN Therapeutic Regimen

ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma who achieve a partial or complete response to first-line chemotherapy.

1 2 3 4 Next › Last »